Identification and Characterization of Selective and High Affinity Small Molecules as Positron Emission Tomography (PET) Imaging Tracers for Pathological Alpha-Synuclein
Objective: The aim is to develop small molecular weight compounds which bind selectively and with high affinity to alpha-synuclein (a-syn) aggregates as diagnostic PET imaging…Fine-mapping of SNCA variants in REM sleep behavior disorder identifies distinct associations
Objective: a). Identify variants in the SNCA locus which affect risk for REM Sleep Behavior Disorder (RBD). b). Test variant effects on rate and type…Digital biomarker sensor feature data reflect quality of life judgements (PDQ39) in recently diagnosed Parkinson’s disease patients
Objective: To evaluate the extent to which data derived from smartphone-based testing and passive monitoring are related to what recently diagnosed Parkinson’s disease (PD) patients…Tau and amyloid-beta inclusions are present in pancreatic beta-cells of patients with synucleinopathies
Objective: We have assessed whether tau and amyloid beta deposits might be present in pancreatic tissue of subjects with Parkinson’s and Lewy Body dementia. Background:…Characterising the role of alpha-synuclein in ferroptotic programmed cell death in the context of Parkinson’s Disease
Objective: Despite the involvement of alpha synuclein (α-syn) pathology in Parkinson's disease (PD) pathology, the consequences on the neuropathology and the type of programmed cell…Targeted deep sequencing of brain DNA for detection of somatic point mutations in synucleinopathies
Objective: To detect relevant somatic "point mutations" (single nucleotide variants- SNVs) in brain-derived DNA in synucleinopathies. Background: There is increasing recognition that neurons may harbour…Systematic Assessment of 10 diagnostic marker candidates in biological fluids for Parkinson’s disease
Objective: To validate in serum and/or cerebrospinal fluid (CSF) diagnostic biomarker candidates identified from a systematic literature search including markers on axonal and synaptic integrity,…Amylin deposition in the brain of Parkinson’s disease patients
Objective: The objective of this study was to determine the presence of amylin deposits in the brain of subjects with synucleinopathies. Background: The link between…Ginsenoside Rb1 Prevents MPTP-Induced Changes in Hippocampal Memory via Regulation of the α-Synuclein/PSD-95 Pathway
Objective: To explore the effects of ginsenoside Rb1 on the cognitive impairment of Parkinson’s disease (PD) model. Background: Memory deficiency is a common non-motor symptom…GBA1 biomarkers in longitudinal CSF: GCase, Sphingolipids and alpha-synuclein
Objective: To assess the GBA1-pathway-specific biomarker profile in patient-derived CSF. Background: Heterozygous mutations in the GBA1 gene represent the most common genetic risk factor for…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 70
- Next Page »